Understanding the difference between fatty liver and normal liver on ultrasound is essential for interpreting scan results and guiding appropriate management. Liver ultrasound is the first-line imaging investigation for suspected liver disease in the UK, offering a safe, non-invasive way to detect hepatic steatosis (fatty liver) and other abnormalities. A normal liver appears uniformly grey with clear vessel definition, whilst fatty liver shows characteristic brightness and reduced clarity of deeper structures. This article explains the key ultrasound features that distinguish healthy liver tissue from fatty infiltration, what these findings mean for your health, and the next steps following your scan results.

Understanding Liver Ultrasound Scans

Liver ultrasound, also known as hepatic ultrasonography, is a non-invasive imaging technique that uses high-frequency sound waves to create real-time images of the liver and surrounding structures. Ultrasound is commonly the first-line imaging modality for investigating abnormal liver blood tests or suspected hepatobiliary disease in the UK, as recommended by the British Society of Gastroenterology (BSG) and the Royal College of Radiologists (RCR) iRefer guidance.

During the procedure, a trained sonographer applies a water-based gel to your abdomen and moves a handheld device called a transducer across your skin. The transducer emits sound waves that bounce off internal organs, creating echoes that are converted into visual images on a monitor. The entire examination typically takes 15–30 minutes and causes no discomfort beyond the pressure of the transducer against your abdomen.

Ultrasound is particularly valuable for detecting:

• Fatty infiltration of the liver (hepatic steatosis)

• Liver size and contour abnormalities

• Masses or lesions within the liver

• Bile duct dilatation

• Blood flow patterns through hepatic vessels

The technique offers several advantages over other imaging modalities, including the absence of ionising radiation, relatively low cost, and widespread availability across NHS facilities. However, ultrasound has important limitations—it is operator-dependent, and image quality can be reduced in patients with obesity or excessive bowel gas. Ultrasound is not recommended for routine monitoring of non-alcoholic fatty liver disease (NAFLD) progression; non-invasive fibrosis tests are preferred for this purpose, as outlined in NICE guidance. For these reasons, your GP may request additional investigations such as FibroScan (transient elastography) or MRI if ultrasound findings are inconclusive or if more detailed assessment of liver fibrosis is required.

What Does a Normal Liver Look Like on Ultrasound?

A healthy liver demonstrates characteristic ultrasound features that sonographers use as reference points when assessing hepatic pathology. Understanding these normal appearances helps clinicians identify deviations that may indicate disease.

Normal liver characteristics on ultrasound include:

Echogenicity (brightness): The normal liver parenchyma appears homogeneous with medium-level echogenicity, typically equal to or slightly brighter than the adjacent kidney cortex and spleen. This uniform grey appearance reflects the consistent cellular architecture of healthy hepatic tissue.

Size and contour: A normal adult liver typically measures approximately 12–15 cm in the midclavicular line, though this varies considerably with body habitus, scanning technique, and individual anatomy. Upper limits of up to 15–16 cm are commonly cited, and measurements should always be interpreted in clinical context rather than as absolute cutoffs. The liver edge should appear smooth and well-defined, with sharp angles at the inferior margin. The surface contour remains regular without nodularity.

Vascular structures: The portal veins appear as bright-walled tubular structures branching throughout the liver, whilst hepatic veins show thinner walls. Blood flow should be clearly visible on Doppler imaging, with normal direction and velocity.

Relationship to surrounding organs: The normal liver demonstrates clear borders with adjacent structures. The diaphragm appears as a bright, curved line above the liver, and the interface between liver and kidney (hepatorenal interface) shows similar echogenicity between the two organs.

The bile ducts within a normal liver are typically not visible on standard ultrasound unless dilated. The common bile duct (CBD) can be measured and typically should not exceed 6–7 mm in diameter in younger adults. However, CBD diameter increases with age and after cholecystectomy (gallbladder removal), where diameters up to 8–10 mm may be normal. These measurements should always be interpreted alongside clinical symptoms and liver blood test results. These baseline parameters allow radiologists to identify subtle changes that may indicate early liver disease, even before symptoms develop.

How Fatty Liver Appears on Ultrasound Imaging

Fatty liver disease, or hepatic steatosis, occurs when fat accumulates within liver cells (hepatocytes), comprising more than 5% of liver weight. This condition produces distinctive ultrasound features that experienced sonographers can readily identify, though the severity of fat infiltration affects the clarity of these findings.

Primary ultrasound features of fatty liver:

Increased echogenicity (brightness): The most characteristic finding is diffuse hyperechogenicity, where the liver appears abnormally bright compared to the kidney cortex. This 'bright liver' appearance results from the increased reflection of sound waves by fat droplets within hepatocytes. In moderate to severe cases, the liver may appear strikingly white on the monitor. It is important to note that increased echogenicity is not specific to fat accumulation—other diffuse liver processes such as fibrosis or certain infiltrative diseases can also increase echogenicity, so findings must be correlated with clinical risk factors and blood test results.

Posterior beam attenuation: As fatty infiltration increases, ultrasound waves are progressively absorbed by the liver tissue, causing deeper structures to appear darker or poorly visualised. This phenomenon, called posterior acoustic attenuation, means that the back portion of the liver and the diaphragm may be difficult to see clearly—a key indicator of significant steatosis.

Vascular blurring: The walls of portal and hepatic veins normally appear as distinct bright lines. In fatty liver, these vessel walls become less defined or 'blurred' due to the surrounding hyperechoic parenchyma, making it harder to trace vascular structures through the liver.

Loss of definition: The normally sharp hepatorenal interface becomes less distinct, and the diaphragm outline may appear hazy rather than crisp.

Fatty liver can be graded as mild, moderate, or severe based on these ultrasound features, though this grading is somewhat subjective. Importantly, ultrasound cannot reliably distinguish between simple steatosis and non-alcoholic steatohepatitis (NASH), nor can it accurately stage liver fibrosis—limitations that may necessitate additional investigations. When quantification of steatosis is required in UK practice, controlled attenuation parameter (CAP) measured during FibroScan or MRI proton density fat fraction (MRI-PDFF) may be used. Similarly, FibroScan or other non-invasive fibrosis tests are needed to assess fibrosis stage, and in selected cases liver biopsy may be required.

Key Differences Between Fatty Liver and Normal Liver on Ultrasound

The distinction between fatty liver and normal liver on ultrasound relies on several comparative features that sonographers assess systematically during examination. Recognising these differences is essential for accurate diagnosis and appropriate clinical management.

Hepatorenal contrast: The most reliable distinguishing feature is the comparison between liver and right kidney echogenicity. In a normal scan, the liver and kidney cortex appear similar in brightness or the liver is only slightly brighter. With fatty liver, the liver becomes noticeably hyperechoic (brighter) compared to the kidney, creating an obvious contrast. This hepatorenal comparison is a useful visual indicator, though it should be noted that the hepatorenal index as a semi-quantitative measure is mainly a research tool and is not routinely standardised or reported across NHS services.

Beam penetration and image quality: Normal liver tissue allows ultrasound waves to penetrate deeply, providing clear visualisation of posterior structures including the diaphragm and deeper vessels. Fatty liver progressively attenuates the ultrasound beam, resulting in poor visualisation of deep liver tissue and posterior structures—the image appears to 'fade out' in the far field.

Vascular clarity: In normal liver, portal vein walls appear as distinct bright lines with clear branching patterns throughout the organ. Fatty infiltration causes these vessels to lose definition, appearing blurred or indistinct against the hyperechoic background. In severe cases, intrahepatic vessels may be barely visible.

Liver edge and contour: Both normal and fatty liver typically maintain a smooth contour in early disease. However, advanced fatty liver disease with progression to cirrhosis may eventually show surface nodularity and irregular margins—though this represents end-stage changes rather than simple steatosis.

Focal versus diffuse changes: Normal liver shows uniform echogenicity throughout. Fatty liver usually demonstrates diffuse involvement, though occasionally 'focal fatty sparing' creates areas of normal-appearing tissue within an otherwise fatty liver, or conversely, focal fatty infiltration may occur in specific regions.

These ultrasound differences guide clinical decision-making, but it is important to recognise that ultrasound has limited sensitivity for detecting mild steatosis (affecting less than 20–30% of hepatocytes) and cannot assess inflammation or stage fibrosis—key factors in determining prognosis and treatment strategies. For these reasons, ultrasound findings must always be interpreted alongside clinical history, risk factors, and liver blood tests.

What Happens After Your Liver Ultrasound Results

Following your liver ultrasound, a radiologist will analyse the images and prepare a formal report for your GP or referring clinician. The turnaround time varies by local NHS service but is typically within 1–2 weeks. The subsequent management pathway depends on whether the scan shows a normal liver or features of fatty liver disease.

If your ultrasound shows a normal liver:

Your GP will discuss the results in the context of why the scan was requested. If you had abnormal liver function tests (LFTs) but a normal ultrasound, further investigations may be needed to identify the cause, such as viral hepatitis screening, autoimmune liver disease markers, or genetic conditions like haemochromatosis. A normal ultrasound provides reassurance but does not exclude all liver pathology, particularly early-stage disease or conditions not visible on ultrasound.

If your ultrasound shows fatty liver:

Your GP will assess the underlying cause and associated risk factors. Non-alcoholic fatty liver disease (NAFLD) is commonly associated with metabolic syndrome, including obesity, type 2 diabetes, hypertension, and dyslipidaemia. Alcohol-related fatty liver disease requires honest discussion about alcohol consumption and may necessitate referral to alcohol support services. The UK Chief Medical Officers recommend that to keep health risks from alcohol low, it is safest not to drink more than 14 units per week on a regular basis. (One unit equals 10 ml or 8 g of pure alcohol—for example, a standard 175 ml glass of 12% wine contains about 2 units.)

Further investigations may include:

For NAFLD, UK guidance recommends initial risk stratification using non-invasive fibrosis scores:

• FIB-4 or NAFLD Fibrosis Score as first-line tests in primary care

• Enhanced Liver Fibrosis (ELF) test if initial scores are indeterminate or suggest increased risk

• Referral to hepatology if ELF score is ≥10.51, indicating advanced fibrosis

• FibroScan (transient elastography) to measure liver stiffness and assess fibrosis stage

• Liver biopsy reserved for cases where diagnosis remains uncertain or to confirm advanced disease

Lifestyle modifications form the cornerstone of fatty liver management:

• Gradual weight loss (7–10% of body weight) through calorie reduction

• Regular physical activity (150 minutes of moderate exercise weekly)

• Mediterranean-style diet rich in vegetables, whole grains, and healthy fats

• Alcohol cessation or reduction to within recommended limits (≤14 units per week)

• Optimisation of diabetes and cardiovascular risk factors

Monitoring and follow-up:

For adults with NAFLD at low risk of advanced fibrosis, NICE recommends repeat non-invasive fibrosis assessment at intervals (for example, every 3 years), rather than routine repeat ultrasound. People with cirrhosis should be offered 6-monthly ultrasound surveillance for hepatocellular carcinoma (HCC), as recommended by NICE guidance on cirrhosis management.

When to contact your GP:

• New or worsening abdominal pain

• Persistent fatigue affecting daily activities

• Unexplained weight loss

• Swelling of abdomen or ankles

Seek urgent same-day assessment or emergency care if you develop:

• Jaundice (yellowing of skin or eyes), especially with fever, severe abdominal pain, or confusion

• Vomiting blood or passing black, tarry stools

• Severe confusion or drowsiness (possible hepatic encephalopathy)

NICE recommends that patients with NAFLD and evidence of advanced fibrosis (ELF ≥10.51) should be referred to hepatology services for specialist assessment. Regular monitoring through repeat non-invasive fibrosis tests helps track disease progression and treatment response, ensuring early detection of complications and optimising long-term liver health.

Frequently Asked Questions